Silo Pharma, Inc. (SILO) stock
SILONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.84−0.07 (-3.66%)
Close on Nov 13, 2026Market cap $2.92MP/E –Yield –
Silo Pharma r&d expenses
Research and development expenses are spending on new products and technology.
Silo Pharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.18M, down 25.7% year over year. For fiscal 2025 it was $2.16M, down 8.8% from the year before. The highest annual figure on record is $2.37M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.16M | -8.8% |
| FY2024 | Dec 31, 2024 | $2.37M | +180.2% |
| FY2023 | Dec 31, 2023 | $845.09K | -34.3% |
| FY2022 | Dec 31, 2022 | $1.29M | +85.4% |
| FY2021 | Dec 31, 2021 | $693.91K | +2543.5% |
| FY2020 | Dec 31, 2020 | $26.25K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $559.09K | +2.8% |
| Q2 FY2026 | Jun 30, 2026 | $298.42K | -58.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.01M | +70.6% |
| Q4 FY2025 | Dec 31, 2025 | $306.01K | -71.6% |
| Q3 FY2025 | Sep 30, 2025 | $543.62K | +5.0% |
| Q2 FY2025 | Jun 30, 2025 | $717.25K | +112.9% |
| Q1 FY2025 | Mar 31, 2025 | $593.96K | +78.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.08M | +69.5% |
| Q3 FY2024 | Sep 30, 2024 | $517.55K | +37.7% |
| Q4 FY2023 | Dec 31, 2023 | $336.97K | +218.9% |
| Q1 FY2023 | Jun 30, 2023 | $333.63K | +95.9% |
| Q4 FY2022 | Dec 31, 2022 | $634.68K | +33.4% |
| Q3 FY2022 | Sep 30, 2022 | $375.80K | +432.9% |
| Q2 FY2022 | Jun 30, 2022 | $105.68K | +6.9% |
| Q1 FY2022 | Mar 31, 2022 | $170.28K | +250.4% |
| Q4 FY2021 | Dec 31, 2021 | $475.95K | – |
| Q3 FY2021 | Sep 30, 2021 | $70.51K | – |
| Q2 FY2021 | Jun 30, 2021 | $98.85K | – |
| Q1 FY2021 | Mar 31, 2021 | $48.60K | – |
See a number that looks wrong?